Moderna's stock is rated Strong Sell at $220.83, with a valuation around $60 per share, implying a 73% downside. This is despite promising Phase 3 melanoma trial results showing a 42% reduction in relapse or death when using intismeran with Keytruda. Challenges remain in commercializing and manufacturing the treatment, and current revenue and cash burn issues widen the gap to the stock's current price. Even optimistic financial models suggest a fair value of only $101 per share, indicating that sustainable free cash flow and broader product success are needed to justify today's valuation.
Moderna's market cap stands at $91.20 billion with a daily trading volume of 9,490,033 shares as of Nov 05, 2026 13:11 WIB. Despite the recent melanoma trial news, the stock price on Pluang is $257.18, down 0.46% for the day, with a majority of order activity at 81% Sell. Typical hold time for Moderna shares on Pluang is 58 days, indicating moderate investor engagement.
